BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week
BullFrog AI (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using artificial intelligence (AI) and machine learning, announced its participation in the TechBio track at Biotech Showcase and RESI JPM during the JP Morgan Healthcare Conference in San Francisco from January 13–16, 2025.
At these events, BullFrog AI will present its proprietary BullFrog Data Networks®, powered by the bfLEAP™ platform. This tool analyzes high-dimension, multi-modal data in specific disease indications, offering a visual representation of previously unknown relationships and pathways. The platform integrates various data sources, including public datasets like the Human Cell Atlas (HCA) and The Cancer Genome Atlas (TCGA), as well as proprietary data.
The BullFrog Data Networks® address the challenge of turning complex datasets into actionable insights, aiding in target identification, understanding mechanisms of action, optimizing clinical trials, and drug repurposing. The platform aims to reduce timelines and improve outcomes in drug development by providing intuitive visual insights and streamlining development processes.
BullFrog AI (NASDAQ: BFRG; BFRGW), una compagnia di sviluppo farmaceutico abilitata dalla tecnologia che utilizza intelligenza artificiale (AI) e apprendimento automatico, ha annunciato la sua partecipazione al TechBio track durante il Biotech Showcase e RESI JPM, che si terranno durante la JP Morgan Healthcare Conference a San Francisco dal 13 al 16 gennaio 2025.
In queste occasioni, BullFrog AI presenterà le sue reti di dati proprietarie BullFrog Data Networks®, alimentate dalla piattaforma bfLEAP™. Questo strumento analizza dati multi-modali ad alta dimensione in specifiche indicazioni di malattia, offrendo una rappresentazione visiva di relazioni e percorsi precedentemente sconosciuti. La piattaforma integra varie fonti di dati, inclusi set di dati pubblici come l'Human Cell Atlas (HCA) e il The Cancer Genome Atlas (TCGA), oltre a dati proprietari.
Le BullFrog Data Networks® affrontano la sfida di trasformare set di dati complessi in intuizioni praticabili, aiutando nell'identificazione degli obiettivi, nella comprensione dei meccanismi d'azione, nell'ottimizzazione delle sperimentazioni cliniche e nel ripristino dei farmaci. La piattaforma si propone di ridurre i tempi e migliorare i risultati nello sviluppo dei farmaci, fornendo intuizioni visive intuitive e semplificando i processi di sviluppo.
BullFrog AI (NASDAQ: BFRG; BFRGW), una empresa de desarrollo farmacéutico impulsada por tecnología que utiliza inteligencia artificial (AI) y aprendizaje automático, anunció su participación en la pista TechBio durante el Biotech Showcase y RESI JPM, que se llevarán a cabo durante la Conferencia de Atención Médica de JP Morgan en San Francisco del 13 al 16 de enero de 2025.
En estos eventos, BullFrog AI presentará sus redes de datos patentadas BullFrog Data Networks®, impulsadas por la plataforma bfLEAP™. Esta herramienta analiza datos multi-modales de alta dimensión en indicaciones de enfermedad específicas, ofreciendo una representación visual de relaciones y caminos previamente desconocidos. La plataforma integra diversas fuentes de datos, incluidos conjuntos de datos públicos como el Human Cell Atlas (HCA) y el The Cancer Genome Atlas (TCGA), así como datos patentados.
Las BulFrog Data Networks® enfrentan el desafío de convertir conjuntos de datos complejos en información práctica, ayudando en la identificación de objetivos, comprensión de mecanismos de acción, optimización de ensayos clínicos y reutilización de medicamentos. La plataforma tiene como objetivo reducir los plazos y mejorar los resultados en el desarrollo de medicamentos al proporcionar información visual intuitiva y simplificar los procesos de desarrollo.
BullFrog AI (NASDAQ: BFRG; BFRGW)는 인공지능(AI)과 머신러닝을 활용한 기술 기반의 의약품 개발 회사로서, 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리는 JP 모건 헬스케어 컨퍼런스의 Biotech Showcase 및 RESI JPM TechBio 트랙에 참여한다고 발표했습니다.
이 행사에서 BullFrog AI는 BullFrog Data Networks®라는 독자적인 시스템과 bfLEAP™ 플랫폼을 소개할 예정입니다. 이 도구는 특정 질병 지표에서 고차원, 다중 모드 데이터를 분석하여 이전에 알려지지 않았던 관계 및 경로를 시각적으로 표현합니다. 이 플랫폼은 Human Cell Atlas(HCA)와 The Cancer Genome Atlas(TCGA) 같은 공공 데이터 세트를 비롯해 독점 데이터를 포함한 다양한 데이터 소스를 통합합니다.
BullFrog Data Networks®는 복잡한 데이터 세트를 실행 가능한 통찰력으로 전환하는 과제에 대응하며, 목표 식별, 작용 메커니즘 이해, 임상 시험 최적화, 약물 재사용 지원에 도움을 줍니다. 이 플랫폼은 직관적인 시각적 통찰력을 제공하고 개발 과정을 간소화하여 약물 개발의 일정을 단축하고 결과를 개선하는 것을 목표로 합니다.
BullFrog AI (NASDAQ: BFRG; BFRGW), une entreprise de développement de médicaments axée sur la technologie utilisant l'intelligence artificielle (IA) et l'apprentissage automatique, a annoncé sa participation à la piste TechBio lors du Biotech Showcase et du RESI JPM au cours de la Conférence sur la santé de JP Morgan à San Francisco du 13 au 16 janvier 2025.
Lors de ces événements, BullFrog AI présentera ses réseaux de données propriétaires BullFrog Data Networks®, alimentés par la plateforme bfLEAP™. Cet outil analyse des données multimodales à haute dimension dans des indications de maladie spécifiques, offrant une représentation visuelle de relations et de voies auparavant inconnues. La plateforme intègre diverses sources de données, y compris des ensembles de données publics tels que le Human Cell Atlas (HCA) et le The Cancer Genome Atlas (TCGA), ainsi que des données propriétaires.
Les BullFrog Data Networks® relèvent le défi de transformer des ensembles de données complexes en informations exploitables, aidant à l'identification des cibles, à la compréhension des mécanismes d'action, à l'optimisation des essais cliniques et à la réutilisation des médicaments. La plateforme vise à réduire les délais et à améliorer les résultats dans le développement de médicaments en fournissant des aperçus visuels intuitifs et en rationalisant les processus de développement.
BullFrog AI (NASDAQ: BFRG; BFRGW), ein technologiegestütztes Unternehmen für die Arzneimittelentwicklung, das künstliche Intelligenz (AI) und maschinelles Lernen nutzt, gab seine Teilnahme an der TechBio-Spur beim Biotech Showcase und RESI JPM während der JP Morgan Healthcare Conference in San Francisco vom 13. bis 16. Januar 2025 bekannt.
Auf diesen Veranstaltungen wird BullFrog AI seine proprietären BullFrog Data Networks® vorstellen, die von der Plattform bfLEAP™ betrieben werden. Dieses Tool analysiert hochdimensionale, multimodale Daten in spezifischen Krankheitsindikationen und bietet eine visuelle Darstellung zuvor unbekannter Beziehungen und Pfade. Die Plattform integriert verschiedene Datenquellen, einschließlich öffentlicher Datensätze wie dem Human Cell Atlas (HCA) und dem The Cancer Genome Atlas (TCGA) sowie proprietären Daten.
Die BullFrog Data Networks® gehen die Herausforderung an, komplexe Datensätze in umsetzbare Erkenntnisse umzuwandeln, die bei der Zielidentifikation, dem Verständnis von Wirkmechanismen, der Optimierung klinischer Studien und der Wiederverwendung von Arzneimitteln helfen. Die Plattform zielt darauf ab, die Zeitrahmen zu verkürzen und die Ergebnisse bei der Arzneimittelentwicklung zu verbessern, indem sie intuitive visuelle Einsichten bereitstellt und die Entwicklungsprozesse rationalisiert.
- Participation in high-profile events like Biotech Showcase and RESI JPM.
- Introduction of BullFrog Data Networks® powered by bfLEAP™ platform.
- Potential for reducing drug development timelines and improving outcomes.
- Demonstrated proof of concept in colorectal cancer and neuropsychiatric indications.
- None.
GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025.
At both Biotech Showcase and RESI JPM, BullFrog AI will highlight its proprietary BullFrog Data Networks®, a data insights tool powered by the bfLEAP™ platform. BullFrog Data Networks® evaluate high-dimension, multi-modal data in specific disease indications, providing a customized, visual representation of previously unknown relationships and pathways. The networks leverage a wide range of data inputs, including publicly available datasets such as the Human Cell Atlas (HCA), The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO), as well as proprietary or custom data sources.
BullFrog Data Networks® address a key challenge faced by pharmaceutical and biotechnology companies: turning vast and complex datasets into actionable insights. The platform uses machine learning to holistically analyze data, revealing hidden insights that manual methods cannot uncover. These insights are presented in an intuitive visual format that enables users to explore individual nodes or clusters, examine relationships, and derive actionable conclusions.
BullFrog AI has demonstrated proof of concept for BullFrog Data Networks® in its own research and development pipeline, focusing on colorectal cancer and multiple neuropsychiatric indications. These networks have a wide range of applications, including target identification and validation, understanding mechanisms of action, optimizing clinical trials, and drug repurposing. By accelerating the generation of novel insights, BullFrog Data Networks® aim to transform approaches to drug development by reducing timelines and improving outcomes.
Powered by the bfLEAP™ platform, BullFrog Data Networks® are purpose-built to deliver answers to critical questions throughout the drug development lifecycle. From early target discovery to understanding drug safety and tolerability, the networks can help streamline development processes and optimize clinical trial design by identifying suitable patient populations for the appropriate trials. BullFrog Data Networks® represent an advancement in the Company's mission to revolutionize drug discovery and development.
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
What is BullFrog AI presenting at Biotech Showcase?
When is BullFrog AI participating in the JP Morgan Healthcare Conference?
What does the BullFrog Data Networks® platform do?
What are the applications of BullFrog Data Networks®?
How does BullFrog Data Networks® benefit drug development?
What datasets does BullFrog Data Networks® use?
What proof of concept has BullFrog AI demonstrated?
